Fig. 4. Activated ILC2s decreased in responder AIT patients. (A) Representative overlay histogram graph of CD69 expression on ILC2s between baseline and 3 days after stimulation with the recombinant antigen-specific protein. (B) Fold change in the mean fluorescence intensity of CD69 expression on ILC2s from healthy (n = 20), AR (AR, n = 20), non-responder AIT (n = 9), and responder AIT (n = 16) in response to allergen-specific stimulation. The data were analyzed by analysis of variance and Tukey's multiple comparison test.

ILC, innate lymphoid cell; AIT, allergen-specific immunotherapy; AR, allergic rhinitis.

^*P < 0.01, ^†P < 0.001.